
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) – Stock analysts at HC Wainwright reduced their Q3 2027 earnings per share estimates for Legend Biotech in a report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of $0.32 per share for the quarter, down from their prior estimate of $0.44. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2027 earnings at $0.48 EPS.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The company had revenue of $359.50 million for the quarter, compared to analyst estimates of $361.46 million. During the same quarter last year, the firm posted ($0.05) earnings per share. Legend Biotech’s revenue was up 32.0% compared to the same quarter last year.
Get Our Latest Stock Analysis on LEGN
Legend Biotech Price Performance
NASDAQ LEGN opened at $15.25 on Thursday. The business has a 50 day simple moving average of $19.17 and a 200 day simple moving average of $22.09. Legend Biotech has a 52-week low of $15.15 and a 52-week high of $37.50.
Institutional Trading of Legend Biotech
A number of institutional investors have recently made changes to their positions in LEGN. Wellington Management Group LLP acquired a new position in shares of Legend Biotech during the 2nd quarter worth about $2,369,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Legend Biotech by 343.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock valued at $7,361,000 after acquiring an additional 315,176 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Legend Biotech by 29.5% in the first quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock valued at $9,439,000 after acquiring an additional 119,000 shares during the last quarter. Tidal Investments LLC increased its position in shares of Legend Biotech by 34.0% in the second quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock valued at $6,945,000 after acquiring an additional 61,023 shares during the last quarter. Finally, Squarepoint Ops LLC increased its position in shares of Legend Biotech by 60.4% in the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock valued at $22,216,000 after acquiring an additional 289,772 shares during the last quarter. Institutional investors own 70.89% of the company’s stock.
Insider Activity at Legend Biotech
In other Legend Biotech news, CFO Carlos Santos sold 5,430 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $9.14, for a total value of $49,630.20. Following the sale, the chief financial officer owned 14,246 shares in the company, valued at approximately $130,208.44. The trade was a 27.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ingrid Zhang bought 20,000 shares of the business’s stock in a transaction on Tuesday, November 17th. The stock was purchased at an average price of $8.16 per share, for a total transaction of $163,200.00. Following the purchase, the chief executive officer directly owned 1,151,860 shares in the company, valued at approximately $9,399,177.60. This represents a 1.77% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.02% of the stock is owned by insiders.
More Legend Biotech News
Investors following LEGN have been watching these news items:
- Positive Sentiment: HC Wainwright maintained its Buy rating and forecasts Legend Biotech will earn $0.24 per share in FY2026, followed by $1.18 per share in FY2027. A separate report cites a brokerage consensus price target of $50.85. Brokerage consensus price target report
- Neutral Sentiment: A recent article asks whether a return to profitability changes the investment case, but the available report details do not specify its conclusions. Yahoo Finance article on Legend Biotech’s return to profit
- Negative Sentiment: HC Wainwright cut its EPS estimates across several upcoming periods: FY2027 to $1.18 from $1.70, Q1 2027 to $0.14 from $0.26, and Q2 2027 to $0.22 from $0.36. It also reduced its Q3 and Q4 2027 forecasts. The broad revisions signal a less favorable earnings outlook and could pressure the shares, although the firm kept its Buy rating. Legend Biotech stock and analyst information
About Legend Biotech
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Recommended Stories
- Five stocks we like better than Legend Biotech
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
